News zum Sektor Gesundheit aus China

 

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

Zacks highlights STNE, UHS, ITGR, and GLDD as value stocks with strong cash flow and growth potential amid earnings and government shutdown concerns....

The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal cell carcinoma patients after progression on first-line therapies The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal cell carcinoma patients after progression on first-line therapies...

Hong Kong stocks fell for a sixth day on Monday, the longest losing streak in nine months, as a flare-up in US-China trade tensions kept investors on edge. The Hang Seng Index fell 2.2 per cent to 25,705.68 as of 10.05am local time, matching a six-day run in early January. The Hang Seng Tech Index dropped 2.5 per cent. On the mainland, the CSI 300 Index slid 1.7 per cent and the Shanghai Composite Index retreated 1.4 per cent. Biotech major WuXi AppTec, which has a huge exposure to the US,......

- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC35 was approximately 14 days, 6-fold longer than tirzepatide, which supports once-monthly subcutaneous (SQ) dosing in humans. - In head-to-head NHP studies, drug exposures of ASC35 intravenous (I.V.) and......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Results presented today at ESGCT 2025 PARIS, France, LUND, Sweden (October 10, 2025) - Genethon, a worldwide pioneer and leader in research and development of gene therapy for rare genetic diseases, and Hansa Biopharma, a Sweden-based leader in IgG cleaving enzyme technology announced today that a patient with a rare liver disease and immunity to the AAV vector has been successfully treated with Genethon's AAV-based GNT0003 gene therapy for Crigler-Najjar syndrome, following prior administration of imlifidase, an enzyme capable of temporarily inhibiting the immune response. This encouraging...

SHANGHAI, Oct. 9, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced it has received the esteemed AAA ESG rating from Morgan Stanley Capital International (MSCI) for the third consecutive year.......

Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...

CKLIFE SCIENCES (00775.HK) announced that its Polynoma will merge with TransCode Therapeutics (RNAZ.US), and they have entered into a share purchase and preferred stock financing agreement.Initially, CKLIFE SCIENCES will hold about 9.1% of TransCode's shares and receive non-voting preferred stock. Once all preferred shares a......

The world's largest glove maker Top Glove Corp. Bhd. expects to expand US sales in fiscal year 2026 even as it faces intensifying competition from Chinese rivals setting up production in Southeast Asia to take advantage of lower American tariffs....

At midday close, HSI rose 11 pts or 0.0% to 26,840. HSTI rose 41 pts or 0.6% to 6,555. HSCEI gained 49 pts or 0.5% to 9,573.Active Heavyweights:MEITUAN (03690.HK) closed at $104.5, up 0.8%BABA (09988.HK) closed at $176.4, down 0.7%XIAOMI (01810.HK) closed at $53.75, down 0.2%TENCENT (00700.HK) closed at $674.5, down 0.1%HSI & HS......

RIO DE JANEIRO, Oct. 8, 2025 /PRNewswire/ -- Anbio Biotechnology participated in the 50th World Small Animal Veterinary Association Congress (WSAVA 2025), an international gathering that brought together veterinarians, researchers, and industry representatives from more than 100 countries.......

STA Pharmaceutical Hong Kong Investment, a shareholder of WUXI XDC (02268.HK), placed 30.3 million shares of WUXI XDC at HKD77.42 per share through Morgan Stanley, Bloomberg reported, citing filing. This represents a discount of nearly 6.5% compared to the closing price of HKD82.8 yesterday (8th).WUXI XDC’s share price cam......

After announcing a 12.97% discounted share placement, IMMUNEONCO-B (01541.HK) opened 5.7% lower this morning (9th) and once bottomed at HKD14.41. It last traded at HKD14.59, down 12.42%, with a volume of 3.992 million shares, involving HKD60.7679 million.IMMUNEONCO-B intends to place 24.2 million new H-shares (5.6% of the enlarg......

CK Life Sciences International is set to merge its subsidiary Polynoma with Nasdaq-listed TransCode Therapeutics, in a move expected to boost the pipeline of anticancer drugs, according to the biotech unit controlled by the Li Ka-shing family. The agreement paved the way for TransCode to acquire the parent company of Polynoma from DEFJ, an indirect wholly owned unit of CK Life, the latter said in a filing with the Hong Kong stock exchange after trading hours on Wednesday. In exchange, TransCode......

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

TransCode acquires 100% of the issued and outstanding interests of Polynoma from CK Life Sciences Concurrent equity investment of $25 Million from CK Life Sciences into TransCode TransCode expands its microRNA-based pipeline with Polynoma's Phase 3-ready seviprotimut-L, a novel polyvalent......

INNOCARE (09969.HK) announced that InnoCare, its wholly-owned subsidiary incorporated in the US, has entered into an exclusive license agreement and a subscription agreement with Zenas (ZBIO.US) for the development, manufacture, and commercialization of orelabrutinib and two other preclinical assets.Under the terms of the licens......